Serhat Sekmek

20PUBLICATIONS
147CO-AUTHORS
Predictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Foetal development and medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Aug 27, 2026
Feasibility and Prognostic Value of an Ovarian NAR-like Score in Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy and Interval Debulking Surgery.

|Jul 28, 2026
Prognostic Significance of the CPS-EG Score in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy.

|Jul 15, 2026
Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study.

|Jun 16, 2026
Low muscle mass predicts poor response to neoadjuvant chemotherapy in advanced ovarian cancer.

|Mar 28, 2026
Clinical Significance of Achieving No Evidence of Disease in HER2-Positive Metastatic Breast Cancer: A Multicenter Study by Turkish Oncology Group (TOG).

Bengü Dursun, Şendağ Yaslıkaya, Serhat Sekmek

|Mar 23, 2026
Real-world effectiveness of total neoadjuvant therapy in locally advanced rectal cancer: a multicenter retrospective study.

Osman Sütcüoğlu, Orhun Akdoğan, İlknur Deliktaş Onur

Pageof 4

Frequent Collaborators

7 joint publications

Dogan Bayram

4 joint publications

Safa Can Efil

3 joint publications

Perihan Perkin

3 joint publications

Fahriye Tugba Kos